published meta-analysis   sensitivity analysis   studies

hydroxychloroquine in COVID-19 prophylaxis - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.68 [0.22; 2.08] COVID-PEP-Post exposure (Boulware), 2020 0.98 [0.02; 49.67] 0.70[0.24; 2.05]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID-PEP-Post exposure (Boulware), 202020%3,318moderatenot evaluable conversion to SARS-CoV- 2–positive status via NP swabdetailed resultsAbella, 2020 2.27 [1.09; 4.76] COVID-PEP-Post exposure (Boulware), 2020 1.21 [0.49; 2.94] Grau-Pujol, 2020 0.45 [0.01; 13.38] PATCH-cohort 3 PreP (Abella), 2020 0.95 [0.23; 3.98] 1.57[0.93; 2.64]Abella, 2020, COVID-PEP-Post exposure (Boulware), 2020, Grau-Pujol, 2020, PATCH-cohort 3 PreP (Abella), 202040%1,345moderatenot evaluable hospitalizationdetailed resultsCOVID-PEP-Post exposure (Boulware), 2020 0.98 [0.06; 15.77] 0.98[0.06; 15.77]COVID-PEP-Post exposure (Boulware), 202010%821lownot evaluable new illness compatible with Covid-19 detailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.86 [0.52; 1.42] COVID PREP (Rajasingham) - HCQ 1x week, 2020 0.73 [0.45; 1.19] COVID PREP (Rajasingham) - HCQ 2x week, 2020 0.74 [0.46; 1.19] COVID-PEP-Post exposure (Boulware), 2020 0.84 [0.55; 1.27] 0.79[0.63; 1.00]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (Rajasingham) - HCQ 1x week, 2020, COVID PREP (Rajasingham) - HCQ 2x week, 2020, COVID-PEP-Post exposure (Boulware), 202040%2,798moderatenot evaluable PCR-confirmed, symptomatic Covid-19 diseasedetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.86 [0.52; 1.42] COVID PREP (Rajasingham) - HCQ 1x week, 2020 0.65 [0.18; 2.33] COVID PREP (Rajasingham) - HCQ 2x week, 2020 1.18 [0.40; 3.50] PATCH-cohort 3 PreP (Abella), 2020 0.95 [0.23; 3.98] 0.88[0.58; 1.33]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (Rajasingham) - HCQ 1x week, 2020, COVID PREP (Rajasingham) - HCQ 2x week, 2020, PATCH-cohort 3 PreP (Abella), 202040%2,102moderatenot evaluable serious adverse eventsdetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.89 [0.44; 1.82] 0.89[0.44; 1.82]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%2,497moderatenot evaluable adverse eventsdetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 20.26 [15.67; 26.20] COVID PREP (Rajasingham) - HCQ 1x week, 2020 0.59 [0.44; 0.79] COVID PREP (Rajasingham) - HCQ 2x week, 2020 2.49 [1.64; 3.79] COVID-PEP-Post exposure (Boulware), 2020 3.32 [2.33; 4.72] 3.16[0.60; 16.68]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (Rajasingham) - HCQ 1x week, 2020, COVID PREP (Rajasingham) - HCQ 2x week, 2020, COVID-PEP-Post exposure (Boulware), 2020499%5,174moderatenot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2020-11-27 15:20 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 657 - roots T: 290